Vnitr Lek 2024, 70(1):40-43 | DOI: 10.36290/vnl.2024.007

Sildenafil in a new innovative dosage form (orodispersible film)

Jiří Slíva
Ústav farmakologie, 3. LF UK, Praha

Erectile dysfunction is characterised by a high prevalence. As part of pharmacotherapy, substances that induce reversible inhibition of phosphodiesterase 5 (PDE-5) have been used for a quarter century. Such an inhibition results in a significantly better filling of the cavernous bodies. A typical representative of this group of drugs is sildenafil. In addition to the classic tablet form, it can be used in the form of an orally dispersible film.

Keywords: erectile dysfunction, phosphodiesterase 5, PDE-5, cGMP, ODF, film - dosage form.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Sildenafil in a new innovative dosage form (orodispersible film). Vnitr Lek. 2024;70(1):40-43. doi: 10.36290/vnl.2024.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Salonia A, Bettocchi C, Capogrosso P, et al. European Association of Urology. 2023. Available on: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2023.pdf (last accessed: January 3, 2024).
    2. Irwin GM. Erectile Dysfunction. Prim Care. 2019 Jun;46(2):249-255. Go to original source... Go to PubMed...
    3. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv.Formul. 2008;2:258-274. Go to original source... Go to PubMed...
    4. Pfister WR, Ghosh TK. Orally disintegrating tablets: products, technologies and development issues. Pharm.Technol. 2005;29:136-150.
    5. Committee for Medicinal Products for Human Use (CHMP). Reflection paper: Formulations of choice for the paediatric population. Available on: https://www.ema.europa.eu/en/formulations-choice-paediatric-population-scientific-guideline (last accessed: July 16, 2023).
    6. Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78:462-469. Go to original source... Go to PubMed...
    7. Cram A, Breitkreutz J, Desset-Brethes S, et al. Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009;365:1-3. Go to original source... Go to PubMed...
    8. Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm 2011;61:117-139. Go to original source... Go to PubMed...
    9. Cupone IE, Sansone A, Marra F, et al. Orodispersible Film (ODF) Platform Based on Maltodextrin for Therapeutical Applications. Pharmaceutics. 2022 Sep 22;14(10):2011. Go to original source... Go to PubMed...
    10. Radicioni M, Castiglioni C, Giori A, et al. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers. Drug Des Devel Ther. 2017 Apr 11;11:1183-1192. Go to original source... Go to PubMed...
    11. Cocci A, Capece M, Cito G, et al. Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film. J Sex Med. 2017 Dec;14(12):1606-1611. Go to original source... Go to PubMed...
    12. Scaglione F, Donde S, Hassan TA, Jannini EA. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation. Clin Ther. 2017 Feb;39(2):370-377. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.